ArticleFrontiers in pharmacology2026
Preclinical activity of SHR-A1921, a novel antibody-drug conjugate targeting trophoblast cell-surface antigen2 (Trop-2) in prostate cancer.
Binyu Wang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.